Physician profile
Robin Jindal
NPI 1821522905
$3,864.36
in general payments reported to CMS, 2019-2025
25 companies · $20.50 in 2025
The $20.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.03 · 2022: $1,107 · 2023: $1,417 · 2024: $1,228 · 2025: $20.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $592.40 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $560.24 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $452.57 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $379.46 | 2021-2024 | |
| Abbvie INC. | $256.44 | 2022-2024 | |
| Pfizer INC. | $237.36 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.55 | 2021-2024 | |
| Amgen INC. | $220.27 | 2022-2024 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $203.46 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $118.62 | 2022-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $100.01 | 2022-2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $83.69 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.14 | 2022-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Phathom Pharmaceuticals, INC. | $62.92 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $52.74 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.98 | 2022 | |
| Seqirus USA INC | $35.67 | 2023 | Flucelvax Quadrivalent |
| Novartis Pharmaceuticals Corporation | $35.05 | 2023 | |
| Lundbeck LLC | $30.05 | 2024 | Rexulti |
| Abbott Laboratories | $24.63 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.18 | 2024 | Nuzyra |
| Edwards Lifesciences Corporation | $17.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2022 | |
| Indivior INC. | $14.54 | 2024 | Sublocade |
| Mylan Specialty L.P. | $14.05 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.